<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-141483</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Daptomycin in home hospitalization</dc:title>
<dc:description xml:lang="en">Outpatient Parenteral Antimicrobial Therapy (OPAT) is widely used in the United States and has advantages for both patients and hospitals. In the last few years, several European countries such as the United Kingdom and Italy have begun to show interest in OPAT, developing this therapeutic modality through distinct healthcare structures. In Spain, the most widely used resources are hospital at home units. Daptomycin is an antibiotic that is administered in a single daily dose, which allows its rapid infusion, and does not require monitoring of plasma levels. These two factors greatly facilitate the ambulatory treatment of severe infections due to Gram-positive microorganisms. The results of clinical trials, case series and post-commercialization registries support the safety and efficacy of the use of daptomycin in OPAT (AU)</dc:description>
<dc:creator>González Ramallo, Víctor José</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El tratamiento antimicrobiano parenteral ambulatorio (OPAT [outpatient parenteral antimicrobial therapy]) es un procedimiento muy extendido en Estados Unidos, que comporta ventajas tanto para el paciente como para los hospitales. En los últimos años, varios países europeos, como Reino Unido o Italia, han empezado a mostrar interés por OPAT, desarrollándolo a través de diferentes estructuras asistenciales. En España, son las unidades de hospitalización a domicilio el recurso más utilizado. La introducción de daptomicina, un antibiótico de administración única diaria, que permite su infusión rápida y que no precisa la monitorización de sus valores plasmáticos, facilita enormemente la ambulatorización del tratamiento de infecciones graves por microorganismos grampositivos. Los resultados de ensayos clínicos, de series de casos y de registros poscomercialización apoyan la eficacia y seguridad del uso de daptomicina en OPAT (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);135(supl.3): 48-54, dic. 2010. tab</dc:source>
<dc:identifier>ibc-141483</dc:identifier>
<dc:title xml:lang="es">Daptomicina en el paciente con hospitalización a domicilio</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d28622^s22083</dc:subject>
<dc:subject>^d8079^s22018</dc:subject>
<dc:subject>^d30071^s22057</dc:subject>
<dc:subject>^d32194^s22074</dc:subject>
<dc:subject>^d6916^s22018</dc:subject>
<dc:subject>^d31518^s22073</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d22431</dc:subject>
<dc:subject>^d32194^s22018</dc:subject>
<dc:subject>^d55416^s22018</dc:subject>
<dc:subject>^d32196^s22018</dc:subject>
<dc:subject>^d11792^s22083</dc:subject>
<dc:subject>^d911^s22000</dc:subject>
<dc:subject>^d31518^s22000</dc:subject>
<dc:subject>^d13411</dc:subject>
<dc:subject>^d8079^s22083</dc:subject>
<dc:subject>^d911^s22073</dc:subject>
<dc:subject>^d30176</dc:subject>
<dc:subject>^d28634^s22083</dc:subject>
<dc:type>article</dc:type>
<dc:date>201012</dc:date>
</metadata>
</record>
</ibecs-document>
